EP0324023A1

EP0324023A1 - Thiosulphinic acid derivatives, their use in the treatment of inflammatory diseases, and drugs containing them

Info

Publication number: EP0324023A1
Application number: EP88907055A
Authority: EP
Inventors: Walter Dorsch; Hildebert Wagner
Original assignee: Roche Diagnostics GmbH; Boehringer Mannheim GmbH
Current assignee: Roche Diagnostics GmbH
Priority date: 1987-07-14
Filing date: 1988-07-12
Publication date: 1989-07-19
Also published as: ATE96024T1; DK113789A; EP0299424A3; EP0299424B1; AU621058B2; HU208114B; WO1989000422A2; US5321045A; DK113789D0; WO1989000422A3; JPH01503713A; KR890701096A; EP0299424A2; FI891210A; DE3885022D1; DE3723248A1; AU2126288A; FI891210A0

Abstract

Thiosulphinic acid derivatives, drugs containing these compounds, and their medicinal use. It has been discovered that thiosulphinic acid derivatives possess excellent anti-inflammatory properties. These compounds are particularly advantageous in the treatment of inflammatory processes induced by the platelet activation factor (PAF) in the bronchi.

Description

Thiosulfinic acid derivatives, their use in the treatment of inflammatory diseases and medicinal products containing these substances.

The invention relates to the use of thiosulfinic acid derivatives for the treatment of diseases in which inflammatory processes are involved in the broadest sense. These diseases include in particular the diseases of the rheumatic type, allergic diseases, asthma, inflammation, which are not included in the aforementioned, and thrombotic diseases.

It is generally known that the ingredients of various plants from the Liliaceae family, in particular the Allium species, have medically advantageous effects. The antibacterial, antifungal and cytostatic effects of garlic have long been known to modern medicine; it also lowers blood pressure, sugar and lipid levels.

From US Pat. No. 2,554,088 it is known that garlic extracts have an antibiotic effect and that the antibiotic effect of the compound is attributable to allyl disulfide oxide. Furthermore, it is known from US Pat. No. 2,508,745 that certain thiosulfinates have antibacterial and fungicidal effects. It has now been found that thiosulfinic acid derivatives of the general formula I

R ₁ - S (O) - S - R ₂

in which R ₁ and R _{2 can be the} same or different and represent an optionally mono- or polysubstituted alkyl radical, aryl radical, aralkyl radical, alicyclic radical or heterocyclic radical,

which either - insofar as they are onion ingredients - can be extracted from the juice of pressed onions (All. cepa) or can be produced chemically, have general anti-inflammatory properties both in vitro and in vivo.

The compounds of the general formula I are in part new substances, but in part their structure does not yet belong to the prior art as regards pharmacological use (see, for example, Rec. Trav. Chim. Pays-Bas 73, 129 (1954)). Common to all is that these compounds have an excellent antiasthmatic, anti-inflammatory, antiallergic, analgesic and also antipyretic effect, they are also suitable for preventing tissue rejection reactions.

According to the invention, thiosulfinic acid derivatives of the general formula are therefore

R ₁ - - S - R ₂ (I), wherein R ₁ and R _{2 have} the meanings given above, optionally in conjunction with a pharmacologically acceptable carrier for use in the treatment or for use in the manufacture of medicaments for the treatment of a disease of the abovementioned type.

An alkyl radical includes straight-chain, branched, saturated and unsaturated alkyl radicals having 1 to 6 carbon atoms, for example a methyl, ethyl, n-propyl, isopropyl, alkyl, 1-propenyl radical, butyl, pentyl and hexyl radical understand. Methyl, ethyl, n-propyl, allyl and 1-propenyl radicals are particularly preferred.

An aryl radical or the aryl part of an aralkyl group is to be understood as an aromatic hydrocarbon radical having 6 to 14 carbon atoms, for example a phenyl, naphthyl or anthryl radical, preferably a phenyl radical.

The alkyl part of the aralkyl groups is formed by straight-chain, branched, saturated or unsaturated alkylene radicals having 1 with 4 carbon atoms, such as methylene, ethylene, vinylene, propylene, propenylene, isopropylene, butylene or ethylethylene.

The optionally provided on the aryl and aralkyl substituents are preferably C ₁ - to C ₆ -alkyl, C ₁ - to C ₆ alkoxy, C ₁ -C ₆ alkylthio, halogen, hydroxyl, formyl, carboxyl, amino, nitro, Cyano, aryloxy, aryl, aralkyl,

where halogen is bromine, chlorine, fluorine or iodine, preferably chlorine or fluorine, aryloxy, for example phenoxy, naphthoxy or anthryloxy, preferably phenoxy represents, aryl has the meaning given above and is preferably phenyl and aralkyl has the meaning given above and preferably means benzyl.

Under an alicyclic radical is an optionally unsaturated cycloaliphatic group with 6 to 10 carbon atoms z. B. a cyclohexyl, cyclopentyl, or cyclohexenyl radical, preferably a cyclohexyl radical.

Among a heterocyclic radical, e.g. B. to understand a pyridinyl, a piperidyl, morpholinyl or tetrahydropyranyl radical.

Unless otherwise specified, the above-mentioned radicals can optionally be substituted by one or more of the following groups, such as, for. B. hydroxyl, formyl, carboxyl, amino, cyano or halogen atoms.

For the compounds that can be isolated from onion juice, it was found that R ₁ = R ₂ = methyl or propyl; that when R _{1 is} methyl or 1-propenyl, R _{2 is} 1-propenyl or methyl, or that when R _{1 is 1} or 1-propenyl, R _{2 is} 1-propenyl or propyl.

The term inflammation, as it is to be understood in the sense of the invention, is generally defined as the reaction of the organism and its tissues against various types of damaging stimuli. Harmful stimuli include exogenous and endogenous stimuli, such as B. tissue injuries, the penetration of foreign bodies, chemical substances, bacterial toxins, allergens, immune complexes, microorganisms, pathological metabolic products and cerium to understand case products of tumors. The classic symptoms of pain and fever are closely linked to the inflammatory process.

It has long been known that certain substances in the body, known as mediators, are closely linked to the inflammatory process. These mediators, which are of extremely great pathogenetic importance, are released from the body cells by the damaging event (noxa). The most important and best-known mediators are histamine, 5-HT (5-hydroxytryptamine), bradykinin, the prostaglandins, prostacyclins, the leukotrienes, thromboxanes and the platelet activating factor that has only recently been researched more recently (hereinafter referred to as PAF). : platelet activating factor).

These and other mediators have an extraordinarily strong effect on smooth muscle contraction, lead to cardiac dysfunction, impair the integrity of blood vessels and mucous membranes, e.g. that of the bronchial system; they also cause the aggregation of platelets and polymorphonuclear leukocytes with the serious consequences of anaphylactic narrowing of the airway, drop in blood pressure, cardiac arrhythmias, plasma exudation, tissue edema, hemoconcentration, thrombocytopenia, leukocytopenia, clumping of the platelet and lymphocytic leukemia and polymorphic disorders.

Due to their wide range of pharmacological effects, their widespread distribution in the organism, their formation through numerous physical, chemical, pathological, pathophysiological and pharmacological influences, and because of their involvement in a variety of pathophysiological processes, the mediators and their pharmacological influence are of the greatest medical importance (cf. The Pharmacological Basis of Therapeutics, Ed.Goodman and Gilman, 6th edition, 1980, McMillan Publishing Company). According to the invention, the use of the thiosulfinic acid derivatives in PAF-induced pathological conditions is preferred, which is why the platelet activating factor (PAF) will be discussed in more detail below.

PAF is a glycerophosphocholine with the chemical name 1-0-alkyl-2-acetyl-sn-glyceril-3-phosphorylcholine. It is made up of a number of cells, e.g. Macrophages, basophils and neutrophils granulocytes etc. released as a result of an allergen-induced activation of these cells. The release of PAF causes a number of the pathological conditions already described above, whereby PAF does not have to act directly, but rather can exert its effect by stimulating further mediators. Recent studies show in particular an important role of PAF in the genesis of clinical bronchial asthma and in other pathological conditions of the lungs, e.g. obstructive bronchitis.

In addition to its important role in the genesis of bronchial asthma and in anaphylaxis, PAF can be regarded as a highly potent inflammation mediator with the pathological effects already described above.

A large number of the mediators mentioned above, including the PAF, are released by a membrane-bound phospholipase from phospholipids of the cell membrane, whereby arachidonic acid and a PAF precursor are formed on the one hand.

Starting from arachidonic acid, two groups of mediators are formed:

i) by the enzyme cyclooxygenase, the prostaglandins including prostacyclin and thromboxane;

ii) by the enzyme lipoxygenase the open chain hydroperoxy and hydroxy acids and especially the leukotrienes. The PAF precursor is converted into the active compound by an acetyltransferase.

Two groups of active substances are pharmacologically important in the treatment of inflammation; on the one hand, there are the so-called non-steroidal anti-inflammatory drugs, which are compounds and derivatives of salicylic acid. Other compounds with known anti-inflammatory activity are the pyrazolone derivatives, the para-aminophenol derivatives, the indole derivatives (e.g. indomethacin) and derivatives of propionic acid. The pharmacological effect of all these compounds is based on the fact that they are able to inhibit cyclooxygenase and thus prevent the synthesis of prostaglandins or thromboxanes.

Salicylic acid or its derivatives and the other compounds of the entire class have a number of serious and very serious side effects. For example, the prolonged administration of salicylic acid derivatives for gastric and intestinal ulceration. Also known are the relative intolerance of the pyrazolone derivatives, the hepatotoxic effect of the para-aminophenol derivatives, the general intolerance of indomethacin and the ulcerative effect of the propionic acid derivatives.

Another serious disadvantage of the non-steroidal anti-inflammatory drugs is that they can possibly increase the pathological effect of the mediators by increasing the substrate for the lipoxygenase and thus for the formation of leukotrienes by the inhibition of the cyclooxygenase.

Opposed to the non-steroidal anti-inflammatory drugs are the steroidal anti-inflammatory drugs, that is the corticosteroids and their derivatives. The anti-logistic effect of the corticosteroids is based on their ability to inhibit both the phospholipase and the lipoxygenase, which inhibits the entire arachidonic acid metabolism. The fatal side effects are disadvantageous for therapy with corticosteroids, of which the following should only be mentioned by way of example: Duodenal or ventricular ulcers, myopathy, osteoporosis, mental disorders, increased susceptibility to infection, subcapsular cataracts and the like.

In addition to the corticosteroids, there are selective lipoxygenase inhibitors, e.g. Benoxaprofen. These substances also have serious side effects, e.g. fatal exfoliative dermatitis (syndrome of scalded skin).

The compounds used according to the invention inhibit both cyclooxygenase, thromboxane synthetase and lipoxygenase and also have the property of blocking PAF-induced effects. They therefore have the properties of steroidal anti-inflammatory drugs, but without their fatal side effects, and are therefore valuable for the treatment of inflammatory processes in the broadest sense, at the origin of which known mediators such as e.g. Prostaglandins, histamine, PAF, leucotrienes and thromboxanes play a role.

In contrast to the non-steroidal anti-inflammatory drugs, which do not act against the leukocyte-induced aspects of chronic inflammatory diseases, since they do not inhibit the formation of leukotriene, the compounds used here are also surprising in this regard because of their surprising, excellent and advantageous action consider known connections.

Anti-inflammatory corticosteroids indirectly inhibit the production of both prostaglandins and leukotrienes, which at least partially explains their excellent therapeutic effects. As described above, treatment with steroids is associated with serious local and also systemic side effects, so prolonged administration of corticosteroids is contraindicated in many inflammatory conditions.

The use of the compounds according to the invention fulfills the requirement for non-steroidal anti-inflammatory agents which are responsible for the synthesis of leucotrienes and Inhibit prostaglandins and thromboxanes and counteract the effects of PAF. They are free from the disadvantages associated with steroidal or non-steroidal anti-inflammatory drugs.

The compounds as well as their pharmaceutically acceptable preparations can then be administered in low doses to achieve a therapeutic anti-inflammatory effect.

The invention is illustrated by the examples given below:

In addition to the compounds mentioned in the examples, the following are preferred for the purposes of the present invention:

S-phenyl 4-bromo-benzenethiosulfinate

S-phenyl 4-chlorobenzenethiosulfinate

S-phenyl 3-methyl-benzenethiosulfinate

S-phenyl 2,4-dimethyl-benzenethiosulfinate

S-phenyl 4-ethoxy-benzenethiosulfinate

4-Chlorobenzenethiosulfinic acid S-4-methoxyphenyl ester

S-4-methoxyphenyl 3-nitro-benzenethiosulfinate

S-phenyl 4-methylthio-benzenethiosulfinate

S-phenyl 4-phenyl-benzenethiosulfinate

S-2-carboxy-phenyl benzene thiosulfipsate

S-phenyl 2-phenoxy-benzenethiosulfinate

S-phenyl pyridine-3-thiosulfinate

S- (2-pyridyl) benzene thiosulfinate

S-benzene thiosulfinic acid (2-naphthyl) ester

S-phenyl naphthalene-2-thiosulfinate

S-2-aminophenyl benzene thiosulfinate

S-4-hydroxyphenyl benzene thiosulfinate

S-2,6-dichloro-phenyl benzene thiosulfinate

S-3,5-di-t-butyl-4-hydroxyphenyl benzene thiosulfinate For example, the compounds for use in the present invention can be isolated from onions by the following method:

example 1

A) Starting material:

Onion juice is obtained from peeled, shredded and homogenized onions (Allium cepa). The homogenate is left to stand for at least 20 minutes before pressing. The pressed juice is shaken twice with dichloromethane, chloroform or other water-immiscible organic solvents; the organic phase is dried over sodium sulfate, filtered off and the solvent is distilled off under reduced pressure. A yellowish-green oily residue is obtained.

This residue is fractionated by chromatographic methods.

B) Fractionation / Method I:

1. For coarse fractionation z. B. column chromatography on silica gel with toluene / ethyl acetate

(10: 3) as Eluens.

2. Then a new column chromatography separation of enriched fractions of the active substances on silica gel with z. B. dichloromethane / acetone (100: 1) as eluent the compounds of the invention.

For this separation step, solvent systems based on chloroform or dichloromethane with additions of 1 to 5% acetone, ethyl methyl ketone, diethyl ether or solvent systems based on hydrocarbons such as heptane, pentane or hexane with additions of 5 to 10% acetone or ethyl methyl ketone are suitable . Example la

B) Fractionation / Method II:

The isolation of the compounds can be simplified as follows, starting from the residue of the organic extraction from onion juice:

1. The triterpenes partially overlapping on silica gel with the substances to be isolated are firstly “flash-chromatographed” on reversed-phase material (eg RP 8 or RP 18) using a hydrophilic eluent (eg methanol ) separated.

2. Then, using medium pressure liquid chromatography (MPLC), the thiosulfinic acid esters can be isolated in one step. Silica gel again serves as the stationary phase, and the solvent mixtures of the second fractionation step from Method I serve as the eluent (see Example 1)

Example 2

Due to the good solubility of the compounds in lower alcohols (e.g. methanol, ethanol), alcohol extraction from e.g. B. lyophilized onion homogenate possible. Subsequently, fractionation can be carried out according to method I (example 1) or II (example la).

Example 3

Extraction:

The onion juice is shaken with organic solvents that are immiscible with water, such as. B.: dichloromethane, chloroform, diethyl ether and other solvents of comparable polarity. Organic solvents of very low polarity such as e.g. B. Petroleum ether are not suitable. Example 4

The juice or the homogenate can also with supercritical gases such. B. CO ₂ extracted under pressure.

According to each of the above examples, six thiosulfinic acid derivatives are obtained with the following formulas:

CH ₃ - -S-CH ₃ (II)

CH ₃ - -S-CH = CH-CH ₃ (III)

(trans)

CH ₃ - -S-CH = CH-CH ₃ (IV)

(cis)

CH ₃ -CH ₂ -CH ₂ - -S-CH ₂ -CH ₂ -CH ₃ (V)

CH ₃ -CH ₂ -CH ₂ - -S-CH = CH-CH ₃ (VI) (cis)

CH ₃ -CH ₂ -CH ₂ - -S-CH = CH-CH ₃ (VII) (trans)

The structures of the compounds VI and VII may be assigned interchanged.

The extracts, fractions and pure substances are stored in the absence of light and oxygen at - 20 ° C. Chromatographic characterization of the thiosulfinic acid esters isolated from onions

1) Thin layer chromatography:

a) Stationary phase: HPTLC prefabricated plates silica gel 60F 254, layer thickness 0.25 mm

b) Mobile phase connection R _f value

Toluene / ethyl acetate (10: 3) II 0.25

III 0.31

IV 0.35 v 0.44

VI 0.46

VII 0, 50

Chloroform / acetone (100: 4) II 0.47

III 0.49

IV 0.49

V 0.54

VI 0.57

VII 0.57

Dichloromethane / acetone (100: 1) II 0.28

III 0, 34

IV 0.38

V 0.37

VI 0.40

VII 0, 44

c) UV behavior:

All thiosulfinic acid esters show a significant reduction in fluorescence in the UV 254. d) Detection behavior:

Spray reagent compound reaction

- Ethanolic sulfuric acid II none 5% / vanillin (1% in EtOH) / 110 ° C III slightly brown-red

IV dto

V none

VI slightly reddish

VII dto

- Palladium (II) chloride solution II yellow-brown 1% in water III brown

IV brown

V light yellow

VI brown

VII brown

- 5% sodium nitroprussite sodium bright red to in water / ethanolic NaIII dto tron lye (10%) IV dto

V dto

VI dto

VII dto

2) High pressure liquid chromatography:

a) Stationary phase: Hibar RT 125-4 finished column; Lichrospher 100 CH-18 / 2.5 µm

b) Mobile phase: acetonitrile / water gradient system

c) detection at 200 nm

d) Retention times:

When using a gradient system from 20% to 80% acetonitrile in 30 min, retention times of 1.80 min (compound II), 4.25 min (compound III), 4.40 min (compound IV), 10.19 min ( Compound V), 9.97 min (Compound VI) and 10.19 min (Compound VII).

Furthermore, the compounds can be prepared chemically by processes known per se for the preparation of analog compounds:

Example 5

S-phenyl benzene thiosulfinate

1.8 g of pyridine are added to a solution of 2.2 g (20 mmol) of thiophenol in 30 ml of dry ether, and a solution of 3.2 g (20 mmol) of benzenesulfinoyl chloride in 20 ml of dry ether is added dropwise with cooling. The mixture is left to stir for 10 minutes, poured into dilute sulfuric acid, the organic phase is separated off, dried and concentrated. There remain 3.2 g of the title compound (68% of theory), mp. 69-70 ° C (from Ligroin). Example 7

Thiosulfinic acid derivatives are obtained in which R ₁ and R _{2 have} the same meaning in analogy to Kametani et al, Jap. J. Pharm. Chem. 31 (1959), p. 60 and Small, Bailey et al J. Am. Chem. Soc - 69, (1947), p. 1712 by oxidation of the corresponding disulfides with an equimolar amount of 3-chloroperbenzoic acid (or perbenzoic acid or peracetic acid) at 0 ° C. in dichloromethane (or trichloromethane or acetic acid).

0.05 mol dipropyl sulfide is dissolved in 300 ml dichloromethane and the solution is cooled in an ice bath. Using a separating funnel, 0.045 mol of 3-chloroperbenzoic acid dissolved in 75 ml of dichloromethane are slowly added dropwise with stirring. The mixture is then stirred for a further 15 min and the precipitate is filtered off. After washing with 300 ml of 5% NaHCO ₃ solution, 3% NaHCO ₃ solution and Aqua dem. the organic phase is dried over Na ₂ SO ₄ and the solvent is stripped off under reduced pressure.

By-products and unreacted dipropyl sulfide were purified by means of chromatotron or flash chromatography on silica gel: First, unreacted dipropyl sulfide is eluted with n-hexane, then propyl thiosulfinate and propyl thiosulfonate are separated with dichloromethane: acetone (100: 1). The oily substance is identified by ultraviolet spectroscopy ( _max = 240 nm (diode array) and HPLC chromatography Rt: 9.9 min.

Reversed phase material with acetonitrile / water gradient elution is used for high pressure liquid chromatography (HPLC). To detect substances without chromophoric groups, detection is carried out at 200 nm. In a universal system for all processed sulfur-containing compounds, the acetonitrile concentration increases linearly from 20% to 80% in 30 min.

The yield is 65% of theory. Th.

Example 8

In an analogous manner as in Example 7 are obtained

a) from dimethyl disulfide, the methylthiosulfinic acid methyl ester. Yield: 50% of theory Th.

Mp: colorless, easily mobile oil

Rt: 1.7 min (HPLC)

UV: _max = 240 nm (diode array)

(The separation of the thiosulfinic acid ester from

Thiosulfonic acid ester occurs in the eluent system

Dichloromethane / acetane (100: 2));

b) from dially disulfide of allyl thiosulfate allyl ester yield: 10% d. Th.

Mp: oil

Rt: 12.3 min (HPLC)

UV: _max = 260 nm (diode array)

Mobile phase: dichloromethane / acetone (100: 1);

and

c) Phenylthiosulfinic acid phenyl ester from diphenyl disulfide Yield: 75% of theory. Th.

Mp: 62-63 ° C

Rt: 18.4 min (HPLC)

UV: _max = 222, 283 nm (diode array)

Solvent system: dichloromethane / n-hexane (1: 1). Example 9

Phenylthiosulfinate and methylphenylthiosulfinate

0.2 mol of thiophenol are dissolved in 500 ml of methanol together with 0.2 mol of dimethyl disulfide with the addition of 80 ml of 1% methanolic KOH and 10 ml of water.

The reaction mixture is 3 hours in the hood; heated to reflux until the HPLC analysis indicates the absence of dimethyl disulfide.

The methanolic solution is then mixed with 300 ml of water and extracted 3 times with 500 ml of n-pentane. The pentane phase is dried and the solvent is distilled off.

The disulfides obtained are then oxidized as in Example 7 and the mixture is worked up accordingly. The pure thiosulfinates are obtained by medium pressure liquid chromatography (MPLC) on silica gel with dichloromethane as the eluent.

I) Methylthiosulfinic acid phenyl ester

oil

Rt: 7.8 min (HPLC)

UV: _max = 223 (sh), 250 nm (diode array)

II) Methyl phenylthiosulfinate

oil

Rt: 9.2 min (HPLC)

UV: _max = 220 (sh), 260 nm (diode array) Example 10

Methyl n-propylthiosulfinate and n-propyl methylthiosulfinate

The two title compounds are prepared from propanethiol and dimethyl disulfide in an analogous manner to that in Example 9.

Example 11

The thiosulfinates isolated from Allium cepa L. can also be obtained by incubating synthesized (+) -alk (en) yl-L-cysteine sulfoxides with an alliinase preparation under suitable conditions.

Example 12

Finally, the compounds can also be prepared starting from sulfinoyl chlorides and thiols, as described by TL Moore, DE O'Connor for analogous compounds (J. Org. Chemistry, 31 (1966), p. 3587).

According to the invention, the connections can be used to treat inflammation of the joints, the skin, the mucous membranes and internal organs, regardless of whether they have been caused by infectious agents, immunological processes or traumas. Inflammatory processes of the bronchial system, such as bronchial asthma or obstructive bronchitis, are particularly advantageous indications to be treated. Furthermore, the compounds can be used for the prophylaxis and treatment of vascular and heart diseases in which it appears desirable to hinder the biosynthesis of inflammatory substances by platelets. The compounds can be used particularly advantageously for the prophylaxis or treatment of all PAF and / or leukotriene-induced phenomena and in particular for the treatment of the bronchial space.

Furthermore, according to the present invention, there is provided a compound of the general formula (I) for use in a method for inhibiting lipoxygenase, cyclooxygenase and thromboxane synthetase in a mammal, for example humans. The invention further provides the use of a compound in the treatment or prophylaxis of a mammal, including humans, particularly for the treatment of any of the diseases or conditions previously described.

The required amount of the compound to be used (hereinafter referred to as the active ingredient) for the therapeutic effect depends on the respective compound, the mode of administration and the subject to be treated, as well as the respective disease. A suitable dose of a compound for administration to a mammal suffering from inflammation, a painful or febrile condition as previously described is from about 0.1 µg to 500 mg of the active ingredient per kilogram of body weight. In the case of systemic administration, the dose can range from 0.5 to 500 mg of the active compound per kilogram of body weight, and the most preferred dose in the range from 0.5 to 50 mg per kilogram of body weight, for example 5 to 25 mg per Kilograms of body weight, which is administered two or three times a day. In the case of topical administration, e.g. B. on the skin or mucous membranes, the appropriate dose may be significantly higher.

While it is possible to administer the active ingredient alone, it is preferred that it be administered in the form of a pharmaceutical formulation containing a compound of the general formula and a pharmaceutically acceptable carrier therefor, usually the active ingredient is one Formulation in a concentration of 0.1 to 99.9 wt .-% of the formulation. Usually a single dose of a formulation contains between 0.1 mg and 1 g of the active ingredient. For topical administration, the concentration of the active ingredient is preferably 1 to 2% by weight of the preparation, but the active ingredient can be up to 10% by weight. Preparations suitable for nasal or buccal administration, such as e.g. B. self-atomizing powder, 0.1 to 20 wt .-%, z. B. 2 wt .-% of the active ingredient.

The preparations for the use according to the invention in veterinary and in human medicine contain the active ingredient in conjunction with a pharmaceutically acceptable carrier and optionally further therapeutically active ingredients. The carrier must be acceptable in the sense that it is compatible with the other ingredients of the formulation and has no adverse effect on the recipient of the formulation.

The formulations are suitably in the form of an oral, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular and intravenous), intra-articular, topical, nasal or buccal administration form.

The formulations are usually in the form of a single dose and can be prepared by any of the methods known in the field of pharmaceutical technology. All methods include the step of bringing the active ingredient into contact with the carrier possibly with one or more additional components. In general, the formulations are prepared by uniformly and intimately mixing the active ingredient with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.

The preparations for oral administration according to the invention may be in the form of discrete units such as capsules, cachets, tablets or lozenges, each form containing a predetermined amount of the active ingredient. They can also be in the form of a powder or in the form of granules or in the form of a solution or a suspension in an aqueous or non-aqueous liquid, or in the form of an oil-in-water emulsion or water-in-oil emulsion . The active ingredient may also be in the form of a bolus, electuary or paste.

A tablet containing the compound can be made by compressing or potting the active ingredient, optionally together with one or more additional ingredients. Compressed tablets can be obtained by pressing the active ingredient in a free-flowing form, e.g. B. as a powder or as granules, optionally mixed with a binder, a lubricant, an inert diluent, surface-active or a dispersant, in a suitable machine. Cast tatlettes can be made by pouring a mixture of the powdered active ingredient and a suitable carrier moistened with an inert liquid diluent in a suitable machine.

The formulations for rectal administration can be in the form of suppositories, the active ingredient in a carrier, e.g. B. cocoa butter, they can also be in the form of an enema. The preparations suitable for parenteral administration usually contain a sterile aqueous preparation of the active ingredient, which is preferably isotonic with the blood of the recipient.

Preparations which are suitable for intra-articular administration can be in the form of a sterile aqueous preparation of the active ingredient, the active ingredient optionally being in microcrystalline form, e.g. B. in the form of an aqueous microcrystalline suspension. In the same way, liposomal preparations or biodegradable polymer systems can be used for the administration of the active ingredient.

Preparations suitable for topical administration contain liquid or semi-liquid preparations, such as. B. liniment, lotions, dressings, oil-in-water or water-in-oil emulsions, such as. B. creams, ointments or pastes, or solutions or suspensions, such as. B. drops. For example, the active ingredient for ophthalmic administration can be in the form of aqueous eye drops, for example in the form of a 0.1 to 1.0% solution.

Preparations suitable for administration through the nose or into the oral cavity are in the form of a self-atomizing powder or in the form of spray preparations, such as, for. B. aerosols. After dispersion, the preparations preferably give a particle size in the range from 10 to 200 μm.

Preparations used according to the present invention can also contain the active ingredient in an aqueous or dilute alcoholic solution. If necessary, the active ingredient can be sprayed into a fine mist that is inhaled by patients. Such preparations usually contain a flavoring agent, such as. B. sodium saccharin and an essential oil. A buffer substance and / or a surface-active agent in preparations of this type can also be used together with preservatives, such as. B. methyl hydroxybenzoate may be included. Other preparations suitable for administration through the nose consist of a coarse powder having a particle size of 20 to 500 µm, which is administered in the same way as snuff.

In addition to the ingredients mentioned above, the preparations for use in accordance with the invention can contain one or more additional ingredients such as e.g. Diluents, buffer substances, flavorings, binders, surface-active agents, thickeners, lubricants, preservatives, e.g. B. methyl hydroxybenzoate (including antioxidants), emulsifiers and the like.

The effect of the compounds of the general formula (I) is then demonstrated on the basis of in vitro and in vivo tests.

1. Investigation of the asthma protective effect of the compounds in vivo. A mixture of compounds 1) (identical to formula III from p. 13) and compound 2) (identical to formula IV from p. 13) was used. The ratio of 1): 2) was approx. 1: 2. Appropriate experiments with guinea pigs were carried out to investigate the asthma protective effect in vivo (Dorsch W. et al., Pflügers Arch. 391, page 263, (1981)).

a) Protective effect in PAF-induced bronchial obstruction.

Seven guinea pigs were either fed the active ingredient in olive oil according to a randomized cross-over protocol or received the carrier olive oil alone. The dose of the active ingredient was 20 mg per kg body weight. 30 minutes later, the animals inhaled 10 μg PAF. The resulting bronchial obstruction was recorded whole-body plethysmographically at 5 min intervals for a period of 30 min (the parameter "compressed air" is used as a measure of the brochial obstruction).

The results are shown in Table 1 below and in Figure 1.

In further experiments, instead of the mixture of compound 1) and 2), compounds were used in which R ₁ and R ₂ CH ₃ (compound 3, cf. Example 8a) or in which R ₁ and R _{2 are} phenyl (compound 4, cf. Ex. 8c). The results are shown in Fig. 2 and Fig. 3. In the case of compound 3) the dose was 50 mg / kg and in the case of compound 4) 100 mg / kg.

It can easily be seen from the table and from FIGS. 1 to 3 that the effect of the administered PAF is significantly weaker in the animals treated with the compounds than in the control animals (larger numbers mean severe asthma). The difference was statistically significant: Fig. 1; 5 min after inhalation p <0.02, 10 min. p <0.001 (Student's t-test for paired data).

b) Protective effect in allergen-induced bronchial asthma in guinea pigs According to a randomized cross-protocol, 9 guinea pigs were either fed the active ingredient in olive oil or the carrier olive oil alone, as described under 1a). The dose of compound administered was 20 mg / kg body weight 30 minutes later, the animals inhaled a 1% ovalbumin solution, the substance to which they had been sensitized 3 weeks before, twice at intervals of 10 minutes for 20 seconds each. The extent of the resulting bronchial obstruction was also recorded whole-body plethysmographically at 2-minute intervals for a period of two 10 minutes (for the method see: Dorsch W., Walter 0., Rosmanith J .: Continuous Recording of Intrapulmonary "Compressed Air" as a Sensitive Noninvasive Method of Measuring Bronchial Obstruction in Guinea Pigs. Pflügers Arch. 391: 236-241 (1981)).

The results of these tests are shown in Figure 4 for the mixture of compound 1) and 2) and in Figures 5 and 6 for compound 3) and 4). Dose administered as in 1a). The figures show that the substances administered significantly weaken the asthmatic response of guinea pigs to the inhalation of an allergen (p <0.05, p <0.05 when comparing the maxima and minima of the asthmatic reaction; Fig. 4; t -Test by Student for paired data).

2. Investigation of the enzyme-inhibiting effect of the compounds in vitro.

The enzyme-inhibiting activity of the compounds was determined in vitro; Use of the mixture of compound 1) and 2).

a) Inhibition of thromboxane biosynthesis of thrombin-stimulated platelet-rich plasma.

Platelet-rich plasma was obtained from a human donor in the usual method and to a platelet count of 90,000 / ml set. This plasma was either incubated with a solvent (1% dimethyl sulfoxide (DMSO) - physiological saline) or with different concentrations of the compounds (see Table II).

Table II: Influence of the compound on the biosynthesis of thromboxane B ₂ in human platelets (pg / ml platelet-rich plasma = pg / 90000 platelets).

5 minutes later, the platelets were stimulated with thrombin (1 or 10 international units = IU) at 37 ° C. After 15 minutes the reaction was quenched with egg cold methanol (volume ratio 1: 1), then by centrifugation at 3000 rpm for 10 minutes. (4 ° C) separately. In the supernatant, thromboxane B _{2 was} determined by radioimmunological methods; the result of this investigation is shown in Table II. It shows that the compounds inhibit the biosynthesis of thromboxane in thrombin-stimulated human platelets in a concentration-dependent manner.

When 0.001 mg / ml to 1.0 mg / ml of compound 3) or compound 4) is used, dose-dependent suppression of thromboxane B ₂ biosynthesis of thrombin-stimulated is found. platelet-rich plasma of a maximum of 61% (compound 3) or 76% (compound 4). b) Inhibition of 5-lipoxygenase activity in isolated porcine leukocytes. Use of the mixture of compound 1) and 2).

The biochemical activity of porcine leukocytes corresponds to that of human leukocytes, that is, direct conclusions can be drawn about the inhibitory activity of the compounds on human granulocytes from the test results described. The enzyme 5-lipoxygenase synthesizes highly potent inflammatory substances from arachidonic acid, namely the leukotrienes LTB ₄ , LTC ₄ and LTD ₄ .

Whole blood from pigs was made non-coagulable using heparin and sodium citrate, then the leukocytes were isolated by dextran sedimentation. After lysing contaminating erythrocytes by hypertonic ammonium chloride solution and washing several times, the cell number was adjusted to 4 × 10 ⁷ cells per ml of phosphate buffer (pH 7.4). The 12-lipoxygenase was selectively blocked by adding 10 μmol eicosatetraynic acid (ETYA). The compounds to be investigated were dissolved in a maximum of 2% ethanolic solution and added to the cell suspensions in the following concentrations: 5, 10, 20 and 30 μmol.

Immediately afterwards, the cells were added by adding calcium ionophore (A 23187, 15 μmol) and radioactively labeled arachidonic acid

( ¹⁴ C-arachidonic acid, 0.7 μmol = 0.1 μCi) stimulated for 5 minutes at 37 ° C

The reaction is stopped by 1% formic acid, the supernatant of the cells is extracted with 2 × 4 ml of ethyl acetate and then separated by means of high pressure liquid chromatography. The result of this test is shown in Table III:

As Table III shows, concentrations of the compounds above 5 μM inhibit the lipoxygenase of porcine leukocytes to 100%. This completely inhibits the formation of leukotrienes.

In addition to the compounds mentioned in the examples, the subject of the present invention is in particular all substances which have any possible combination of the substituents mentioned in the examples.

Claims

1. Use of thiosulfinic acid derivatives of the general formula (I)

R ₁ - -SR ₂ (I)

in which R ₁ and R ₂ , which may be the same or different, mean an optionally mono- or polysubstituted alkyl radical, aryl radical, aralkyl radical, alicyclic radical or heterocyclic radical, for the treatment of inflammatory diseases.

2. Use of thiosulfinic acid derivatives of the general formula (I)

R ₁ - SSR ₂ (I)

in which R ₁ and R ₂ , which may be the same or different, mean an optionally mono- or polysubstituted alkyl radical, aryl radical, aralkyl radical, alicyclic radical or heterocyclic radical, for the preparation of medicaments for the treatment of inflammatory diseases.

3. Use of a compound according to any one of claims 1 and 2, wherein R ₁ and / or R _{2 is} a C _1-6 alkyl, phenyl, naphthyl, anthryl, benzyl, phenetyl, cyclohexyl, cyclopentyl, pyridinyl -, piperidyl, morpholinyl or tetrahydropyranyl radical, these radicals optionally having one or more hydroxyl, formyl, carboxyl, amino or cyano groups and halogen atoms or in the case of phenyl, naphthyl, benzyl, phenethyl and Anthrylrests also by one or more C ₁ - may be substituted to C ₆ alkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ alkylthio, aryloxy, aryl, or aralkyl groups.

4. Use of a compound according to any one of claims 1 to 3, wherein R ₁ = R ₂ = methyl or propyl.

5. Use of a compound according to any one of claims 1 to 3, wherein when R _{1 is} methyl or 1-propenyl, R _{2 is} 1-propenyl or methyl.

6. Use of a compound according to any one of claims 1 to 3, wherein when R _{1 is} propyl or 1-propenyl, R _{2 is} 1-propenyl or propyl.

7. Use of a compound according to any one of claims 1 to 3, wherein R ₁ and / or R _{2 is} optionally substituted phenyl.

8. Use of a compound according to any one of claims 1 to 6, wherein the compound has one of the following formulas:

CH ₃ -S- CH ₃ (II)

CH ₃ - -S-CH = CH-CH ₃ (III)

(trans)

CH ₃ - -S-CH = CH-CH ₃ (IV)

(cis)

CH ₃ -CH ₂ -CH ₂ - -S -CH ₂ -CH ₂ -CH ₃ (V)

CH ₃ -CH ₂ -CH ₂ - -S-CH = CH-CH ₃ (VI)

(cis)

CH ₃ -CH ₂ -CH ₂ - -S-CH = CH-CH ₃ (VII)

(trans)

9. Use of a compound according to any one of claims 1 to 8 for the treatment of bronchial asthma.

10. Use of a compound according to any one of claims 1 to 8 for the treatment of general allergic diseases.

11. Use of a compound according to any one of claims 1 to 8 for the treatment or prophylaxis of obliterating vascular diseases.

12. Use of a compound according to any one of claims 1 to 8 as a lipoxygenase inhibitor.

13. Use of a compound according to any one of claims 1 to 8 as a cyclooxygenase inhibitor.

14. Use of a compound according to any one of claims 1 to 8 for the treatment of PAF-induced inflammatory conditions.

15. Use of a compound according to spoke 1 to 8 for the treatment of diseases of the rheumatic type such as polyarthritis.

16. A method for producing a compound according to claim 8, in which

(i) Onions (Allium cepa) homogenized and after

If onion juice or a lyophilisate is obtained at room temperature,

(ii) the onion juice or the lyophilisate is extracted in the former case with a polar, water-immiscible solvent or in the latter case with a lower alcohol or under pressure with a supercritical gas

and

(iii) the extract is separated into its constituents by separation processes known per se.

17. The method according to claim 16 in which one

(i) Onions (Allium cepa) homogenized, the

Allow homogenate to stand at room temperature for at least 20 min and then use it to make onion juice,

(ii) shake the onion juice twice with dichloromethane, chloroform or other water-immiscible organic solvents, dry the organic phase over sodium sulfate and distill off the solvent under reduced pressure;

(iii) the residue coarsely fractionated by column chromatography on silica gel using toluene / ethyl acetate as the eluent, (iv) the active component is subjected to a new chromatographic separation on silica gel, the dichloromethane or chloroform being eluted with an addition of 1-5% acetone or ethyl methyl ketone or diethyl ether or eluent systems based on hydrocarbons such as heptane, pentane or hexane with additions of 5 - 10% acetone or ethyl methyl ketone used.

18. The method according to claim 17, in which the step

(ii) residue obtained by means of flash chromatography on reversed-phase material using a hydrophilic eluent, roughly fractionated and the active ingredient then by medium pressure liquid chromatography (MPLC) on silica gel using one of the solutions mentioned in step (iv) in claim 16 as the eluent separates.

19. Pharmaceutical preparation containing at least one of the compounds according to claim 1 to 8 or obtained according to claim 16, 17 or 18 for use as an anti-inflammatory agent.

20. A pharmaceutical preparation according to claim 19 for use in the treatment of bronchial asthma.

21. A pharmaceutical preparation according to claim 19 for use in the treatment of PAF-induced inflammatory conditions.

22. Pharmaceutical preparation according to claim 19 for use in the treatment of diseases of the rheumatic type, such as polyarthritis.

23. Thiosulfinic acid derivatives of the general formula I

R1- -S-R2 (I ')

in the

R ₂ 'and R ₂ ' can be the same or different and represent an optionally mono- or polysubstituted alkyl radical, aryl radical, aralkyl radical, alicyclic radical or heterocyclic radical,

where if R ₁ 'is an allyl group, R ₂ ' is also not an allyl group and, if R ₂ 'is a methyl group, R ₂ ' is also not a methyl group,

for use as an anti-inflammatory agent.

24. Compounds of general formula I 'according to claim 23 for use in the treatment of bronchial asthma.

25. Compounds of general formula I 'according to claim 23 for use in the treatment of PAF-induced inflammatory conditions.

26. Compounds of general formula I 'according to claim 23 for use in the treatment of diseases of the rheumatic type, such as polyarthritis.

27. Thiosulfinic acid derivatives of the general formula I ″

0 R ₁ - -SR ₂ (I "), in the

R ₁ "is an optionally mono- or polysubstituted alkyl radical, aryl radical, aralkyl radical, alicyclic radical, or heterocyclic radical

and

R ₂ "denotes an optionally substituted α, β-unsaturated alkyl radical.

28. Thiosulfinic acid derivatives of the formulas

CH ₃ -S-CH = CH-CH ₃ (III)

(trans)

CH ₃ - -S-CH = CH-CH ₃ (IV)

(cis)

CH ₃ -CH ₂ -CH ₂ -S-CH ₂ -CH ₂ -CH ₃ (V) o

CH ₃ -CH ₂ -CH ₂ - -S-CH = CH-CH ₃ (VI)

(cis)

CH ₃ -CH ₂ -CH ₂ - -S-CH = CH-CH ₃ (VII)

(trans).